Sanofi (SAN.PA)

77,64 +0,20 (+0,26 %) À partir de 10:00AM CEST. Marché ouvert.

Sanofi

54, Rue La BoEtie
Paris 75008
France
33 1 53 77 40 00
https://www.sanofi.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers—General
Employés à temps plein: 95 442

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Paul Hudson	CEO & Director	5,64M	S.O.	1967
Mr. Jean-Baptiste Chasseloup de Chatillon	Exec. VP & CFO	S.O.	S.O.	1965
Mr. Laurent Gilhodes	Principal Accounting Officer and VP of Corp. Accounting	S.O.	S.O.	S.O.
Mr. Bruno Ménard	Chief Information officer	S.O.	S.O.	S.O.
Dr. Josephine Fubara	Chief Science Officer of Consumer Health Care	S.O.	S.O.	S.O.
Eva Schaefer-Jansen	Head of Investor Relations	S.O.	S.O.	S.O.
Mr. Dante Beccaria	Global Compliance Officer & VP	S.O.	S.O.	S.O.
Mr. Roy Papatheodorou	Exec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. Integrity	S.O.	S.O.	1978
Mr. Josep Catlla	Head of Communications	S.O.	S.O.	S.O.
Mr. Pierre Chancel	Sr. VP of Global Diabetes and Sr. VP of Global Marketing	S.O.	S.O.	1957

Les montants ont été établis en date du 31 décembre 2021 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Sanofi en date du 1 septembre 2022 est 3. Les scores principaux sont Audit : 3; Société : 5; Droits des actionnaires : 5; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.